Namaste! Main ek Equity Research Analyst ke roop me aapke liye Evexia Lifecare Ltd (pehle Kavit Industries Ltd ke naam se jani jati thi) ka detailed fundamental analysis prastut kar raha hoon.
Yeh ek Penny / Micro-cap company hai aur iska data kaafi volatile aur alag-alag sources par slightly vary karta hai. Main Screener.in aur publicly available verified sources se latest data (February 2026) ka use kar raha hoon.
1️⃣ Business Model & Work
- Company exactly kya kaam करती hai? Evexia Lifecare ki history bohot badalti rahi hai. Initially yeh Edible Oils aur Petrochemicals me the. 2020 ke baad inhone apna business Pharma Chemicals ki trading me pivot kiya. Abhi company mainly Pharma Chemical Trading, Personalised Healthcare Solutions, Diagnostic Labs, aur Plastic Reprocessing Plants ke business ko claim karti hai.
- Revenue ka main source kya hai? Puraana aur majority revenue abhi bhi Chemicals aur Agriculture produce ki bulk trading se aata hai, halanki company health-tech aur UAE me clinics acquire karne (Vittals Medicare) ke claims kar rahi hai.
- Domestic vs Export exposure: Mainly Domestic (India), but recently inka focus UAE me healthcare clinics (ARCCL) ke expansion par gaya hai. (Detailed export revenue breakup: DATA NOT AVAILABLE)
- Industry me company ka role aur competitive advantage: Company ka koi distinct competitive advantage ya moat nahi hai. Trading business me margins bohot patle (thin) hote hain aur barriers to entry low hain.
2️⃣ Industry & Sector Analysis
- Sector ka current status: Pharma APIs aur Chemical trading kaafi competitive aur working-capital intensive sectors hain. Global supply chain disruptions aur Chinese dumping ka is par bada asar padta hai.
- Sector cyclical ya secular? Trading businesses inherently Cyclical aur low-margin hote hain. Healthcare/Diagnostic sector secular hai, par Evexia ka core operation abhi bhi us level par prove nahi hua hai.
- Growth drivers: India ka ‘China Plus One’ strategy API/Pharma chemicals ke liye positive hai. Healthcare aur diagnostics demand post-Covid rapidly grow kar rahi hai.
- Major competitors: Chemical trading me kayi unorganized aur organized players (jaise Shiv Texchem) hain. Diagnostics me badi giants (Dr. Lal PathLabs, Metropolis) inke competitors hain.
3️⃣ Latest Financial Performance (STRICT DATA RULE)
Data Source: Screener.in / Trendlyne (Consolidated TTM basis up to Dec 2025/FY25 estimate).
| Financial Metric | FY 2022 | FY 2023 | FY 2024 | FY 2025 (TTM/Est) | Latest Qtr (Dec 2025) |
| Revenue (Cr) | ₹75.51 | ₹69.55 | ₹56.27 | ₹96.67 | ₹24.60 – ₹25.24 |
| OPM % | 3.19% | 0.83% | 3.48% | 2.84% | ~0.99% – 1.67% |
| PAT (Cr) | ₹0.80 | ₹1.99 | ₹1.15 | ₹0.83 | ₹0.29 – ₹0.41 |
| ROE (%) | DATA NOT AVAILABLE | 1.64% | 1.27% | ~0.25% – 0.32% | – |
| ROCE (%) | DATA NOT AVAILABLE | 1.25% | 0.26% | ~0.13% – 0.30% | – |
- Debt/Equity: ~2.16 (Screener.in) se lekar 7.0 (Finology) tak variation hai due to different consolidation models. However, debt heavy structure hai.
- Interest Coverage: Poor. (Operating profit is hardly covering interest expenses).
- Free Cash Flow trend & quality: FCF lagataar negative raha hai kyuunki debtor days (paisa market me fasa hona) bohot high hain (~300 – 381 days).
4️⃣ Management & Shareholding (Latest Only)
(Data as of Dec 2024 / Mar 2025)
- Promoter holding & pledged shares: Promoters ke paas sirf 3.49% holding bachi hai. Yeh ek bohot bada Red Flag hai.
- FII / DII / Mutual Fund holding trend: FII (0.16%) aur DII (0.10%) negligible hai.
- Public Holding: Market ka lagbhag 96.25% hissa Public ke paas hai (Retailers aur kuch foreign SPVs / Funds jaise Aio Growth Capital, Wave Capital etc.).
- Management track record: Promoter (Mr. Jayesh Thakkar) aur board ne pichle kuch saalo me multiple baar business line change ki hai (Edible oil -> EV -> Pharma -> Plastics -> Healthcare). Aisi drastic pivots execution risk badhate hain aur trust kam karte hain.
5️⃣ Valuation (Latest Market Data Only)
(Stock Price as of Feb 20, 2026: ~₹1.50 | Market Cap: ~₹285 Cr)
| Valuation Metric | Current Value | 5-Year Average | Peer Comparison |
| PE Ratio | 152.0 – 177.6 | DATA NOT AVAILABLE | Sector PE is ~41.7x |
| PB Ratio | 0.53 – 0.69 | DATA NOT AVAILABLE | Peers usually trade above 1.5x |
| EV/EBITDA | ~293x | DATA NOT AVAILABLE | Highly overvalued relative to peers |
- Fair value approach: Earnings almost zero ke barabar hone ke kaaran P/E ratio completely skewed aur artificially high (170x+) dikhta hai. Relative valuation metrics isko ek highly speculative stock sabit karte hain jisme value ki bhari kami hai.
6️⃣ Future Growth Triggers (3–5 Years)
- Acquisitions: Inhone UAE based healthcare company (Vittals Medicare) aur DiponEd Bio (Stem cell research) me stakes liye hain. Agar in acquisitions se aane wale saalo me positive cash flows generate hote hain, toh hi fundamental growth aayegi.
- FCCB Issuance: Company ne USD 100 million raise karne ka plan announce kiya tha. Agar yeh actual me deploy hokar return banata hai toh trigger ho sakta hai.
7️⃣ Present Situation (Current Outlook)
- Stock ka current phase: Pichle 1 saal me stock me kareeb 45% – 48% ka bada downfall aaya hai. Yeh purely ek “Penny Stock” ki tarah trade kar raha hai.
- Recent developments ka impact: Naye JVs aur investments ki sirf announcements par price ek baar jump karta hai aur fir dump ho jata hai. Numbers me in announcements ka asar (PAT growth) completely missing hai.
- Short-term vs Long-term outlook: Short-term technical bounces aa sakte hain (operators dwara), lekin Long-term outlook fundamentally bohot weak hai jab tak Debt kam nahi hota aur ROE double-digit me nahi aata.
8️⃣ Risk & Red Flags
- Promoter Holding (Red Flag): Sirf 3.49% holding hona darshata hai ki promoters ka apni hi company par vishwas nahi bacha ya unhone apna risk retail par shift kar diya hai.
- High Debtor Days (Financial Risk): Paisa collect karne me 300+ din lag rahe hain, iska matlab company fake sales book kar rahi ho sakti hai ya cash aane ki guarantee zero hai.
- Frequent Business Changes (Governance Risk): Ek hi choti si company Edible Oil, Pharma, Plastics aur Dubai Hospitals—sab me kaam karne ki baat karti hai, jo reality se zyada paper announcements lagti hain.
- Continuous Equity Dilution: Pehle shares split kiye gaye aur preferential warrants issue kiye gaye, jisse retail investors ki equity dilute hui hai.
9️⃣ Final Verdict
- Evexia Lifecare ek pure speculative / operator-driven penny stock hai jisme strong fundamentals ki bhaari kami hai.
- Sales sirf trade basis par book ho rahi hain, profits negligible hain, aur balance sheet weak hai.
- Promoter holding ka 3.49% hona sabse bada danger sign hai kisi bhi long-term investor ke liye.
- Conservative Investor Suitability: STRICTLY AVOID. Yeh aapki capital ko puri tarah erode kar sakta hai.
- Aggressive Investor Suitability: AVOID. Agar aap penny stocks pasand karte hain, tab bhi is stock me margins aur return on capital itne kharab hain ki risk-reward aapke favour me nahi hai.
- Approximate target range & risk-reward: No Target (Zero visibility of sustainable earnings). Risk is 100% of capital erosion.
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pahle apne Financial Advisor se salah zarur lein.